Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
The need for an effective HIV/AIDS vaccine is imperative to halt a pandemic that involves more than 40 million individuals worldwide as of 2005 and is causing enormous socio-economic losses, especially in developing countries (DC). The overall failure of more than two decades of HIV vaccine research justifies the demands for a concerted effort for the rapid development of new and efficacious vaccines against HIV/AIDS. In this context, building international collaborative networks is a must for speeding up scientific research and optimizing the use of funding in a synergistic fashion, as resources for HIV/AIDS are limited and do not involve most of the biggest Pharmas that are more interested in drug discovery. The AIDS Vaccine Integrated Project (AVIP) consortium is an example of synergistic partnership of international European Union and DC experts with a common research goal. AVIP is a European Commission-funded (FP-6), consortium-based, 5-year program directed to the fast development of new HIV/AIDS vaccine candidates to be tested in phase I clinical trials in Europe for future advancement to phase II/III testing in DC. To ensure their rapid development, AVIP novel combined vaccines include both regulatory and structural HIV antigens, which have already been tested, as single components, in phase I clinical trials. In particular, such combination vaccines may be superior to earlier vaccine candidates, the vast majority of which are based only on either structural or regulatory HIV products. In fact, the generation of immune responses to both types of viral antigens expressed either early (regulatory products) or late (structural products) during the viral life cycle can maximize immune targeting of both primary or chronic viral infection. Further, the rational design of combined vaccines allows exploitation of immunomodulatory functions of HIV regulatory proteins, which can improve immunity against structural vaccine components. The building of the AVIP consortium and its scientific strategy will be reviewed in this paper as an example of the establishment of a consortium regulated by a specific intellectual property agreement.
Ferrantelli
Flavia
F
National AIDS Center, Istituto Superiore di Sanità, V. le Regina Elena 299, 00161, Rome, Italy.
Buttò
Stefano
S
Cafaro
Aurelio
A
Wahren
Britta
B
Ensoli
Barbara
B
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D003906:Developing Countries; D005062:European Union; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007391:International Cooperation; D013019:South Africa; D017778:Vaccines, Combined / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
D016915:AIDS Vaccines; D015488:HIV Antigens; D017778:Vaccines, Combined